Emcitate

Emcitate is a medicine used to treat peripheral thyrotoxicosis (excess blood levels of certain thyroid hormones) in people with monocarboxylate transporter 8 (MCT8) deficiency. MCT8 deficiency is also known as Allan-Hernon-Dudley syndrome, a disorder affecting brain development. Emcitate contains the active substance tiratricol and is a hybrid medicine. This means that it is similar to a reference medicine containing the same active substance, but that there are certain differences between the two. Emcitate is available as dispersible tablets (to be mixed with water before being taken), while the reference medicine was available as tablets to be taken by mouth. The reference medicine for Emcitate is Téatrois, which was marketed in France for the treatment of thyroid hormone resistance syndrome. MCT8 deficiency is rare, and Emcitate was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 November 2017. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1945).